Drugs that contain Ombitasvir; Paritaprevir; Ritonavir

1. Drug name - TECHNIVIE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8642538 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Sep, 2029

(6 years from now)

US8420596 ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors
Apr, 2031

(8 years from now)

US8691938 ABBVIE INC Anti-viral compounds
Apr, 2032

(9 years from now)

CN103819537A ABBVIE INC Anti-Viral Compounds
May, 2017

(5 years ago)

CN104193729A ABBVIE INC Antiviral Compound
Sep, 2017

(5 years ago)

CN106986861A ABBVIE INC Antiviral Compound
Jun, 2020

(2 years ago)

CN103819459B ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN103819459A ABBVIE INC Antiviral Compound
May, 2021

(1 year, 4 months ago)

CN102641271B ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Aug, 2021

(1 year, 1 month ago)

CN102641271A ABBVIE INC Hepatitis C Serine Protease Inhibitor Of Macrocyclic Compound
Aug, 2021

(1 year, 1 month ago)

CN101775017B ABBVIE INC Macrocyclic Compounds Of Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

CN101775017A ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

CN103172620A ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103172620B ABBVIE INC Antiviral Compound
Jun, 2030

(7 years from now)

CN102333772A ABBVIE INC Anti-Viral Compounds
Jun, 2030

(7 years from now)

CN102333772B ABBVIE INC Antiviral Composition
Jun, 2030

(7 years from now)

CN103209686A ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103209686B ABBVIE INC Solid Composition
Jun, 2031

(8 years from now)

CN103153988B ABBVIE INC Antiviral Compound
Oct, 2031

(9 years from now)

CN103153988A ABBVIE INC Anti-Viral Compounds
Oct, 2031

(9 years from now)

CN103354808A ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103354808B ABBVIE INC Antiviral Compound
Dec, 2031

(9 years from now)

CN103596941A ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

CN103596941B ABBVIE INC Antiviral Compounds
Feb, 2032

(9 years from now)

CN108350016A ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

CN108350016B ABBVIE INC Antiviral Tetrahydrofuran Derivatives
Sep, 2036

(13 years from now)

IN287227B ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

IN200907222P1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2954892B1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2954892A1 ABBVIE INC Solid Compositions
Jun, 2020

(2 years ago)

EP2468285B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468285A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468286A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2805726B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468287B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2805726A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468286B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2468287A1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Sep, 2029

(6 years from now)

EP2340029A4 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2340029A2 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2340029B1 ABBVIE INC Macrocyclic Hepatitis C Serine Protease Inhibitors
Jan, 2030

(7 years from now)

EP2455376A1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2337781B1 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2628481B1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2628481A1 ABBVIE INC Trisubstituted Heterocycles As Replication Inhibitors Of Hepatitis C Virus Hcv
Jun, 2030

(7 years from now)

EP2337781A2 ABBVIE INC Anti-Viral Compounds To Treat Hcv Infection
Jun, 2030

(7 years from now)

EP2455376B1 ABBVIE INC Heterocyclic Compounds As Inhibitors Of Hepatitis C Virus (Hcv)
Jun, 2030

(7 years from now)

EP2368890B1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890A1 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2368890B9 ABBVIE INC Hepatitis C Virus Inhibitors
Jun, 2030

(7 years from now)

EP2579854B1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854B2 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2579854A1 ABBVIE INC Solid Compositions
Jun, 2031

(8 years from now)

EP2692346A1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2692346B1 ABBVIE INC An Antiviral 1-Phenyl-2,5-Dibenzimidazol-5-Yl-Pyrrolidine Derivative
Oct, 2031

(9 years from now)

EP2678334B1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

EP2678334A1 ABBVIE INC Anti-Viral Compounds
Feb, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8399015 ABBVIE INC Solid pharmaceutical dosage form Aug, 2024

(1 year, 10 months from now)

US8268349 ABBVIE INC Solid pharmaceutical dosage form Aug, 2024

(1 year, 10 months from now)

US8399015

(Pediatric)

ABBVIE INC Solid pharmaceutical dosage form Feb, 2025

(2 years from now)

US8268349

(Pediatric)

ABBVIE INC Solid pharmaceutical dosage form Feb, 2025

(2 years from now)

US9006387 ABBVIE INC Anti-viral compounds Jun, 2030

(7 years from now)

US9044480 ABBVIE INC Compositions and methods for treating HCV Apr, 2031

(8 years from now)

US8686026 ABBVIE INC Solid compositions Jun, 2031

(8 years from now)

US8420596

(Pediatric)

ABBVIE INC Macrocyclic hepatitis C serine protease inhibitors Oct, 2031

(9 years from now)

Treatment: Treatment of hcv infection using ombitasvir; Treatment of hcv infection using paritaprevir

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
12.5MG;75MG;50MG TABLET;ORAL Discontinued

availability in other generic markets.

Click on the highlighted region to filter.